

# Dyadic International Inc

03:59 28 Mar 2019

## Dyadic International rounds out 2018 with nine research collaborations, two more in the 1Q

Dyadic International Inc (OTCMKTS:DYAI) announced Wednesday that it had closed out 2018 with nine funded proof-of-concept research collaborations and two new collaborations this year.

The Jupiter, Florida-based biotechnology platform company, engages in the development, and large scale manufacture of low-cost enzymes and other proteins for diverse market opportunities in the United States and Europe.

READ: Dyadic International says up-listing to the NASDAQ is 'part of the plan' It leverages its proprietary C1 expression system to help bring biologic vaccines, therapeutic enzymes, proteins, biosimilars and drugs to market faster and at a lower cost.

"2018 was another year of continued progress with many favorable milestones," said Dyadic CEO Mark Emalfarb, while emphasizing that the company had inked nine funded research collaborations in 2018.

Dyadic has a research collaboration with Mitsubishi Tanabe Pharma Corp to express two therapeutic compounds using its C1 production platform. It also has one with Sanofi-Aventis Deutschland GmbH, to express the potential of its C1 technology to produce various types of therapeutic compounds for manufacturing protein-based vaccine and biologic drugs.

In 2018, the company also inked a proof of concept research collaboration to produce different types of biologic vaccines and drugs of interest for human and animal health applications, with the Israel Institute of Biologic Research (IIBR), a top 20 pharmaceutical company and two top tier academic institutions, including the Structural Genomics Consortium, which is part of the University of Oxford and the Fraunhofer USA Center for Molecular Biotechnology.

"In the first quarter of 2019, we signed two new research collaboration agreements both with top twenty-five pharmaceutical companies," said Emalfarb. "These programs demonstrate that the market and the industry are taking notice of Dyadic and the perceived capability of our C1 gene expression platform."

### Eyeing Nasdaq

In January this year, the company filed an application to list its stock on the tech-laden Nasdaq stock exchange.

"We expect that our application will be approved by Nasdaq provided we maintain the minimum stock price requirement and clear the outstanding comments," said Emalfarb. "We believe a NASDAQ listing will broaden our shareholder base by attracting new investors and ultimately, build long-term shareholder value."

### Financial highlights

Research and development revenue for the year ended December 31, 2018, increased to approximately \$1,295,000

**Price:** US\$4.08

**Market Cap:** US\$109.2M

### 1 Year Share Price Graph



### Share Information

**Code:** DYAI

**Listing:** NASDAQ

52 week	High	Low
	\$4.87	\$1.40

**Sector:** Pharmaceuticals

**Website:** [www.dyadic.com](http://www.dyadic.com)

### Company Synopsis:

*Dyadic International, Inc. is a global biotechnology company focused on further improving and applying its proprietary C1 expression platform to help speed the development and lower the cost of biologic vaccines and drugs for animal and human health applications.*

### Author:

**Proactive Investors Ltd**

**+44 (0)207 989 0813**

**action@proactiveinvestors.com**

compared to \$758,000 for the year ended December 31, 2017.

As of December 31, 2018, cash and cash equivalents were approximately \$2.4 million compared to \$5.8 million at December 31, 2017. The carrying value of investment grade securities, including accrued interest as of December 31, 2018 was \$39.1 million compared to \$43.3 million at December 31, 2017.

Contact Uttara Choudhury at [uttara@proactiveinvestors.com](mailto:uttara@proactiveinvestors.com)

Follow her on Twitter: [@UttaraProactive](https://twitter.com/UttaraProactive)

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 [action@proactiveinvestors.com](mailto:action@proactiveinvestors.com)

#### No investment advice

Proactive Investors is a publisher and is not registered with or authorised by the Financial Conduct Authority (FCA). You understand and agree that no content published constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.